Category list : Scottish Medicines Consortium

Sort by: Newest first Oldest first A-Z Z-A

  • Multiple myeloma ss oct 17

    Daratumumab recommended for treatment of multiple myeloma in Scotland

    18 OCT 2017 14:14

    The Scottish Medicines Consortium (SMC) has recommended daratumumab (Darzalex) for use as a fourth-line treatment option in multiple myeloma.

  • Antiretroviral pre-exposure prophylaxis (PrEP) treatment

    Scotland will fund pre-exposure prophylaxis for people at high risk of HIV

    12 APR 2017 13:51

    People in Scotland at risk of HIV will be able to access pre-exposure prophylaxis (PrEP) treatment on the NHS.

  • Close up of the breast cancer drug, Kadcyla

    Breast cancer drug deemed too expensive in England has been approved in Scotland

    11 APR 2017 13:46

    NHS Scotland has approved the use of breast cancer drug Kadcyla, which was rejected for use in England on the grounds that its benefits did not justify its cost.

  • Shona Robison, Scottish health minister

    End-of-life and orphan drug assessments to be reformed in Scotland

    20 DEC 2016 13:43

    The way that medicines for end-of-life, orphan and ultra-orphan conditions are approved in Scotland is to be reformed, following the publication of the ‘Montgomery review’. 

  • Breast cancer cells

    Cancer charities say patients are being denied access to new drugs

    16 AUG 2016 16:43 By Debbie Andalo

    NHS cancer patients are missing out on innovative new drugs which are available in other European countries because of a flawed assessment and pricing system, according to a report published by cancer charities Breast Cancer Now and Prostate Cancer UK.

  • February 2016: SMC decisions Subscription

    2 MAR 2016 10:09

    The Scottish Medicines Consortium has approved the following medicines for use in NHS Scotland for specific indications: fulvestrant (Faslodex; AstraZeneca); golimumab (Simponi; Merck Sharp and Dohme); guanfacine (Intuniv; Shire); panobinostat (Farydak; Novartis); and ulipristal acetate (Esmya; Gedeon Richter).  Eculizumab (Soliris; Alexion), pixantrone (Pixuvri; CTI Life Sciences) and teduglutide (Revestive; NPS Pharma) have not been recommended for use.

  • Scottish health secretary Shona Robison (pictured) has announced a review into how new drugs are assessed for NHS use

    Scottish government announces review of how medicines are assessed for NHS use Subscription

    1 FEB 2016 16:04

    The Scottish government has announced an independent review into the way that new drugs are assessed for use in the NHS that will report back to ministers by summer 2016.

  • January 2016: SMC drug approvals Subscription

    20 JAN 2016 14:40

    The Scottish Medicines Consortium has accepted the following drugs for use in the NHS in Scotland during the January 2016 drug appraisals: Eperzan (albiglutide; GSK), Trulicity (dulaglutide; Eli Lilly), Akynzeo (netupitant/palonosetron; Eisai), Nexavar (sorafenib; Bayer) and Jinarc (tolvaptan; Otsuka). Full details of restrictions can be found on the

  • December 2015: SMC decisions Subscription

    9 DEC 2015 9:32

    The Scottish Medicines Consortium has accepted the following medicines for use in NHS Scotland for particular indications: efavirenz (Sustiva; Bristol-Myers Squibb); glatiramer acetate (Copaxone; Teva); naloxegol (Moventig; AstraZeneca); ceritinib (Zykadia; Novartis).

  • November 2015: SMC decisions Subscription

    16 NOV 2015 16:57

    The Scottish Medicines Consortium has accepted the following medicines for use in NHS Scotland: atazanavir and cobicistat (Evotaz; Bristol-Myers Squibb); edoxaban (Lixiana; Daiichi Sankyo), for two separate indications; pembrolizumab (Keytruda; Merck Sharp and Dohme), as monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults previously untreated with ipilimumab; tiotropium/olodaterol (Spiolto Respimat; Boehringer Ingelheim); and triamcinolone hexacetonide ...

Show  10 per page20 per page50 per page

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.